Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To study the effects of short (6 months) and longer‐term (up to 24 months) growth hormone (GH) replacement therapy using a dose titration regimen, on lipid and glucose metabolism in GH‐deficient, hypopituitary adults. DESIGN: On‐going open study of GH treatment up to 24 months. Measurements were performed at baseline and at 6, 12, 18 months and 2 years during therapy (data shown at 6 months and 2 years only). Using a dose titration regimen the median GH dose used to achieve and maintain IGF‐I levels above the median, but below the upper limit of the age‐related reference range (median IGF‐I 202.5 μg/l, range 76–397 μg/l), was 1.2 IU daily (range 0.4–3 IU) [0.8 IU/day, males; 1.6 IU/day, females]. PATIENTS: Ninety GH‐deficient hypopituitary adults (54 female, median age 48 years, range 19–79 years) entered the study and 24 (14 female, median age 45 years, range 32–79 years) have concluded the 2 year period of assessment. MEASUREMENTS: Body mass index (BMI), waist and hip circumference ratio (WHR), fasting lipids, glucose and glycated haemoglobin (HbA 1c) levels were measured at 6 month intervals during GH therapy. RESULTS: Using the dose titration regimen, compared to pretreatment values, total and low density lipoprotein (LDL)‐cholesterol levels were significantly lower at 6 months (mean ± SEM, 5.61 ± 0.1 vs. 5.25 ± 0.1, and 3.85 ± 0.19 vs. 3.43 ± 0.26, respectively, P < 0.05), and were maintained throughout the study. Male patients had significantly lower pretreatment total and LDL cholesterol levels than females (mean ± SEM, 5.33 ± 0.16 mmol/l vs. 5.7 ± 0.12 mmol/l and 3.8 ± 0.23 mmol/l vs. 3.92 ± 0.29 mmol/l, respectively, P < 0.05). A decrease in total cholesterol was confined to patients with pretreatment total cholesterol levels above 5.8 mmol/l; patients with the highest pretreatment cholesterol levels (> 6.4 mmol/l) obtained the greatest cholesterol reduction (mean ± SEM, 7.13 ± 0.14 mmol/l vs. 5.76 ± 0.31 mmol/l, P < 0.05). A cholesterol‐lowering effect of GH therapy was evident in patients who had elevated pre‐GH total cholesterol levels even if they were already receiving and continuing lipid lowering medication (mean ± SEM, 5.62 ± 0.22 vs. 5.03 ± 0.285, P < 0.05). A modest increment in high density lipoprotein (HDL)‐cholesterol was evident at 18 months but there was no significant change in triglycerides at any time point. Fasting plasma glucose increased significantly at 6 months but remained within the reference range. Glycated haemoglobin increased significantly at 6 months and was maintained throughout the study; one patient developed frank diabetes mellitus while receiving treatment. There was a weak but significant correlation between the increment in glycated haemoglobin and pretreatment BMI (r = + 0.215, P < 0.05). CONCLUSION: The effect of GH on lowering total and low density lipoprotein‐cholesterol is more prominent in patients with higher pretreatment cholesterol levels and is evident even in patients receiving other lipid‐lowering medication. A modest increment in mean fasting glucose (within the reference range) and mean glycated haemoglobin persisted throughout the study. One patient developed diabetes mellitus. A GH replacement regimen using low dose and careful titration to avoid elevated IGF‐I levels and adverse effects is associated with sustained beneficial effects on circulating lipids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
Carroll, P. V., Christ the members of Growth Hormon, E. R., Bengtsson, B. Å., Carlsson, L., Christiansen, J. S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4594 · Cited by 822 · cited 1×
“Earlier studies using weight or surface area based doses have shown improvement in many features ascribed to GHD including a reduction in total and low density lipoprotein (LDL)-cholesterol levels (Carroll et al., 1998).”
BackgroundIncreased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
Markussis, V., Beshyah, S. A., Johnston, D. G., Fisher, C., Nicolaides, A. N., & Sharp, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)92892-j · Cited by 390
The growth hormone deficiency syndrome in adults
Cuneo, R. C., Salomon, F., McGauley, G. A., & Sönksen, P. H. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02347.x · Cited by 375 · cited 1×
“…previously documented favourable effects of GH therapy in hypopituitary adults, particularly in relation to the metabolic pro®le, have all used high dose regimens, frequently associated with serum IGF-I levels above the normal range (Cuneo et al., 1992; Beshyah et al., 1995; Weaver et al., 1995).”
Backgroundvan den Berg, G., Veldhuis, J. D., Frölich, M., & Roelfsema, F. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.7.8675561 · Cited by 293 · cited 1×
“Since women need more GH to achieve a normal IGF-I level than men, males are more likely to be overtreated (Van den Berg et al., 1996; Drake & Monson, 1999).”
Background
Cited by
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Role of the GH/IGF-1 axis in lifespan and healthspan: Lessons from animal models
Berryman, D. E., Christiansen, J. S., Johannsson, G., Thorner, M. O., & Kopchick, J. J. (2008) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2008.05.005 · Cited by 288
Optimizing GH Therapy in Adults and Children
Drake, W. M., Howell, S. J., Monson, J. P., & Shalet, S. M. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.4.0438 · Cited by 185
Self-citationAdult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement
Reed, M. L., Merriam, G. R., & Kargi, A. Y. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00064 · Cited by 119
“An overall beneficial effect on serum lipid profile (reduction in total and LDL cholesterol and improvement in HDL cholesterol) has been noted with GHRT in some studies, but data are inconsistent (Florakis et al., 2000; Maison et al., 2004).”
Result
Metadata
- Authors
- Florakis, D., Hung, V., Kaltsas, G., Coyte, D., Jenkins, P. J., Chew, S. L., Grossman, A. B., Besser, G. M., & Monson, J. P.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2000-10
- Volume
- 53
- Issue
- 4
- Pages
- 453-459
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W1970734380
- Cited by
- 69
- References
- 7
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. https://app.cochat.ai/papers/10.1046/j.1365-2265.2000.01108.x
- The paper
- Florakis, D., Hung, V., Kaltsas, G., Coyte, D., Jenkins, P. J., Chew, S. L., Grossman, A. B., Besser, G. M., & Monson, J. P. (2000). Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2000.01108.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.